The Impact of Delay Presentation on Staging and Clinicopati Subtypes in Breast Cancer Patients
Article Sidebar
Main Article Content
Abstract
Background: More than 50 percent of breast cancer patients die related to disease. The earlier detection and treatment offers chance to reducing mortality. The clinicopathological subtypes of breast cancer are used to guide therapeutic choice and defined prognosis.
Objective: To evaluate the relationships between the delay in presentation and staging, clinicopathological subtypes in breast cancer patients.
Methods: From tumor registry Surin hospital, the medical records were reviewed in 108 breast cancer patients during October 1st, 2009 to September 30th ,2010. The collected data were age, duration of symptom to first hospital visit, duration of symptom to definite treatment, tumor size, staging, histologic grading and clinicopathological subtypes. Descriptive statistics and Chi-square test were employed to data analysis.
Results: Twenty nine percent (32/108) of patients with symptoms more than 12 weeks before their first hospital visit (delay in presentation) and 59.4 percent (19/32) of this patients had locally advanced or metastatic disease compared with only 26.3 percent (20/76) of those with duration less than 12 weeks (p = 0.0001). The clinicopathological subtypes of breast cancer in delay presentation patients were Luminal B 40.6 percent, HER-2 overexpression 31.3 percent and Tripple negative 25 percent
Conclusion: The longer delay presentation of symptoms are associated with more advanced or metastatic disease in breast cancer patients and worst clinicopathological subtype
Keywords: Breast cancer, delay in presentation, staging, clinicopathological subtypes
Article Details
References
2. National Cancer Institute. Previous version : SEER Cancer Statistics Review, 1975-2008. [online]. 2011 [cited 2012 Sep 11]; Availablefrom:URL:https://seer.cancer.gov/csr/1975__2008.
3. Burgess CC, Ramirez AJ, Richards MA, Love SB.Who and what influences delayed presentation in breast cancer?. Br J Cancer 1998;77:8:1343-8.
4. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in presentation and treatment of symptomatic breast cancer.Br J Cancer 1999;79:5-6 :858-64.
5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. et al. Strategies for subtypes-dealing with the diversity of breast cancer : highlights of the St Gallen international expert concensus on the primary of early breast cancer 2011. Ann of Oncology 22:8:1736-47.
6. Fisher ER, Redmond C, Fisher B. A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer 1997;40:6:3160-7.
7. Rossi S, Cinini C, Di Pietro C, Lombardi CP, Crucitti A, Bellantone R, et al Diagnostic delay in breast cancer : correlation with disease stage and prognosis. Tumor 1990;76:6:559-62.
8. Wilkinson GS, Edgerton F, Wallace HJ Jr, Reese p, Patterson J, Priore R-. Delay, stage of disease and survival from breast cancer. J Chron Dis 1979;32:5:365-73.
